JEFFREY MARTZ: Open Payments
NPI 1376013771 · KELLER, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,313 in 73 payments from 21 companies in 2025. Trend: 2023 $1,245 · 2024 $515 · 2025 $1,313
Food & beverage: $1,313
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $218 |
| Novo Nordisk Inc | 8 | $143 |
| Otsuka America Pharmaceutical, Inc. | 8 | $140 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $135 |
| Lilly USA, LLC | 6 | $108 |
| PFIZER INC. | 5 | $97 |
| Astellas Pharma US Inc | 3 | $57 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| Amgen Inc. | 3 | $45 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
Products named: VRAYLAR, REXULTI, CAPLYTA, MOUNJARO, Ozempic, NURTEC ODT, Veozah, QULIPTA.
Industry payments across TX — which companies pay providers there.
